OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma
RMAT designation reduces BLA application review time and permits augmented interactions with FDA to inform market access
NEW YORK, June 06, 2025--(BUSINESS WIRE)--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. RMAT designations are granted to sponsors with regenerative medicine therapies for serious or life-threatening conditions and provide sponsors with various benefits, including eligibility for an accelerated Biologics License Application (BLA) review.
OST-HER2 has already received Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for osteosarcoma from the U.S. FDA. If OST-HER2 receives a conditional BLA via Accelerated Review prior to September 30, 2026, the Company will become eligible to receive a Priority Review Voucher (PRV) that it intends to immediately sell. The most recent publicly disclosed PRV sale, valued at $155 million, occurred in May 2025.
The Company is awaiting feedback by mid-June 2025 from a Type D meeting with FDA regarding the statistical analysis plan to be used in an End of Phase 2 meeting for OST-HER2 in the prevention of metastases in recurrent, fully-resected, lung metastatic pediatric osteosarcoma. Upon receipt of the Type D Meeting feedback, the Company intends to promptly request the End of Phase 2 meeting with FDA in which it will be seek agreement to allow it to begin a rolling BLA submission in the third quarter of 2025. The grant of the RMAT designation in the third quarter of 2025 complements the company's parallel efforts in other major markets, including Europe and the United Kingdom, where the company plans to seek EMA PRIME Designation and Conditional Market Access (CMA) applications.
In parallel to regulatory engagement and market access planning for OST-HER2, the Company is preparing for the late stage clinical development of other pipeline candidates. As such, the Company is well positioned for sustained growth across multiple therapeutic modalities.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company has demonstrated positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a BLA to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.
In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the U.S. FDA and other risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250602523393/en/
Contacts
OS Therapies Contact Information: Jack Doll410-297-7793Irpr@ostherapies.com
https://x.com/OSTherapies https://www.instagram.com/ostherapies/ https://www.facebook.com/OSTherapies/ https://www.linkedin.com/company/os-therapies/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Design Group Americas Voluntarily Files for Chapter 11 Protection, Initiates Sale Process Aimed at Maximizing Value Through Going Concern Transactions
BERWICK, Pa.--(BUSINESS WIRE)--IG Design Group Americas, Inc. and its domestic subsidiaries (collectively, 'DGA' or the 'Company'), a design, manufacturing, sourcing, and distribution company of branded and private label consumer products, announced today that it has voluntarily filed for chapter 11 relief in the United States Bankruptcy Court for the Southern District of Texas (the 'Court') to facilitate a court-supervised marketing and sale process pursuant to section 363 of the Bankruptcy Code. The Company intends to pursue a value maximization strategy by engaging with buyers who are interested in purchasing certain of the Company's business segments as a going concern, while concurrently winding down its domestically manufactured woven ribbon products business and supporting assets. DGA includes over 50 product categories and brands, some of which were established over a century ago. Like many companies in the consumer products sector, DGA has been navigating a challenging operating landscape for several years, compounded by the loss of a major customer, who entered liquidation and significantly impacted DGA's revenue as well as new trade tariffs imposed in 2025 that increased operational costs, affected pricing strategies, and contributed to reduced customer orders. The Company's decision to pursue an in-court process was driven by liquidity constraints, substantial working capital requirements, and the seasonal nature of significant portions of its business. 'Following DGA's sale to an affiliate of Hilco Capital Group, we have worked diligently with our advisors to evaluate the optimal path forward for the business,' said Sue Buchta, Chief Executive Officer of DGA. 'We enter the court-supervised sale process in dialogue with multiple interested parties for certain of our business segments as a going concern and intend to leverage chapter 11 to maximize the value of our assets. We thank our employees, customers, and partners for their support and will work diligently to minimize any potential impact during the process.' Additional Information about the Court-Supervised Process DGA has secured an agreement for approximately $53 million in committed debtor-in-possession ('DIP') financing from an affiliate of Hilco to support its value maximizing strategy throughout its Chapter 11 cases, subject to Court approval. Additionally, to uphold its commitments to its stakeholders, DGA has filed several customary 'first day' motions. These motions, upon approval by the Court, will provide authorization for the continued payment of employee wages and benefits arising under programs that were in effect as of the petition date, the maintenance of certain customer programs, payments to certain critical vendors for prepetition amounts owed, payment to vendors for amounts owed on post-petition goods and services delivered to the Company, and other relief measures standard in these circumstances. DGA's non-U.S. affiliates are not part of the chapter 11 cases and will continue to operate while the Company considers the impact of asset sales and the optimal plan to maximize the value of the interests it holds in those subsidiaries. Additional information is available at Stakeholders with questions may call the Company's claims agent Kroll, toll-free at (877) 307-2977 (U.S. and Canada) or (646) 290-6127 (International), or email at dgateam@ Advisors Latham & Watkins LLP is serving as legal counsel, Huron Consulting Group LLC is serving as financial advisor and investment banker, and C Street Advisory Group is serving as strategic communications advisor to DGA. About DGA Design Group Americas (DGA) is a diverse group of companies operating across multiple regions, categories, seasons, and brands. The company employs over 1,400 people and works with customers in the US and around the world, with offices and operations in the United States, UK, Australia and Asia. DGA products are found in over 100,000 retail outlets internationally, with products reaching millions of consumers of all ages. Design Group Americas creates, designs, and manufactures products that help the world celebrate life's special occasions. They are proud to serve the best retailers around the globe with a complete end-to-end service from design to distribution. Design Group America's products are found within six core categories: Gift packaging: DGA is one of the world's largest producer of celebrations products, including gift wrap, gift bags, ribbons & bows Party: Party-ware, balloons and accessories Ribbon: Craft, décor, ribbon for branded or floral business Craft: Craft and creative play products that empower consumers of all ages to express themselves, learn new skills, as well as create individual looks, unique gifts and keepsake items Stationery: Wide range of stationery products for consumers of all ages, for use in education, commercial, and home settings including both standard and fashion ranges Homeware/Décor: Seasonal and everyday décor such as florals, holiday signs, tabletop décor and ornaments
Los Angeles Times
3 hours ago
- Los Angeles Times
Here's how to get GLP-1 drugs covered by employer health insurance
While the new anti-obesity medications known as GLP-1s are only one tool to combat obesity and cardiometabolic disease, they have changed the medical landscape and are clinically important in treating these diseases. Yet most Americans who have health insurance cannot get coverage for them. For some, the only option has been to resort to compounded drugs for which the Food and Drug Administration has not assured the safety, and for which the main pharmaceutical ingredient is made in Chinese chemical factories without the quality standards of FDA-approved branded drugs. Even that inferior option is going away, as the FDA has declared that the name-brand drugs are no longer in short supply and so the off-brand drugs are no longer allowed. President Trump recently called out 'the fat shot' when he told pharmaceutical companies to offer the United States the same pricing they offer other peer nations. He related a story of a friend in London who told him the price of GLP-1s there is about one-tenth of what it would cost in the U.S. The average listed price in the U.S. is more than $1,000 a month. In England, it is about $150. There is not yet legislative authority to require pharmaceutical companies to sell prescription drugs in the United States at lower prices, but there is a straightforward way that these medications can become affordable to many in the United States. Most employee health insurance coverage is through employer-sponsored plans, in which the budget is based on premiums contributed by both the employer and employee. Few plans provide coverage for any weight loss treatment, but if they did, it would have to fit in that budget — which would probably necessitate raising premiums. Toxic fat is the cause of many cardiometabolic conditions, and GLP-1 drugs can help people reclaim their health. Improving access and affordability could be transformative for public health, given that about 88% of Americans are metabolically unhealthy. Increasingly, employees are telling their employers that they want access to these medications, and many employers would like to offer plans that cover them. The brand-name manufacturers themselves provide a clue to how this could be possible. They offer their drugs directly to patients for around $500 a month. The sticking points? People whose employee-sponsored health insurance would cover even part of the cost of weight loss drugs are not eligible for that reduced price. Also, at $500 a month, even the discounted direct-to-consumer price still makes the drugs unaffordable to many. Drug pricing in the United States is not transparent, and many entities get a share of the dollars that the health plans have budgeted. Simplifying the system with the GLP-1 drugs could make these drugs more accessible. Today, a drug bought from the drug company at $1,000 can include around a $300 rebate negotiated by a pharmacy benefit manager (working on behalf of the employer-sponsored health plan) and is often accompanied by a $150 manufacturer's discount coupon. The resulting price is similar to the around $500 price that drug companies offer directly to patients who don't have coverage for these drugs. If we eliminate the rebates and coupons, so that manufacturers only charge employer-sponsored health plans the same $500 price they charge consumers directly, and then allow employers to contribute part of the cost (say $300 a month), we can get the out-of-pocket costs for employees close to the price at which these drugs are sold in other countries. It would be a rebate-free, coupon-free system with reasonable cost sharing by the employer. The only reason that system of rebates even came to exist was to create enticements so certain manufacturers could persuade pharmacy benefit managers and employee-sponsored health plans to favor their drug over others'. But in this case, where only two main drugs exist and both have publicly available clinical trial data that physicians can use to make informed prescribing decisions, rebates aren't needed. In reality, recent agreements between pharmacy benefit managers and drug manufacturers have prioritized financial interests over clinical appropriateness, determining drug preference based on what benefits the companies, not what's best for the patient. Getting the price of the drugs to an affordable level would significantly remove one of the most despised aspects of the healthcare system — prior approval authorization. Doctors' offices are expending resources to get around barriers erected to limit the use of healthcare plan dollars on expensive medications for those the insurance plan and its managers determine do not need the drug, even when the doctors believe they do. GLP-1s are highly effective for most people, but they also have some serious risks. We should leave it to doctors to make shared decisions with their patients about whether the risks outweigh the benefits. To further create incentives for the pharmaceutical companies to reduce their prices and for employers to share in the cost of these drugs, the Trump administration should agree, as the Biden administration did, to cover them under Medicare. (Trump reversed that effort this year, barring Medicare and Medicaid from using them to treat the disease of obesity.) This plan to simplify payments and expand access would not make all drugs affordable in the United States, but increasing accessibility to GLP-1s can get us on the road to eliminating the significant problem of cardiometabolic disease and improving our health. David A. Kessler, a former commissioner of the Food and Drug Administration, is the author of 'Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight.'
Business Wire
3 hours ago
- Business Wire
Shift4 Announces Date of Initial Preferred Stock Dividend
CENTER VALLEY, Pa.--(BUSINESS WIRE)--Shift4 Payments, Inc. ('Shift4' or the 'Company') (NYSE: FOUR), announced today, in connection with the 10,000,000 shares of 6% Series A Mandatory Convertible Preferred Stock issued on May 5, 2025, that its Board of Directors has declared a dividend of $1.45 per share to be paid in cash on August 1, 2025 to holders of record as of the close of business on July 15, 2025. Subject to the terms of the Mandatory Convertible Preferred Stock, and as described further in the prospectus supplement filed by the Company with the Securities and Exchange Commission on May 2, 2025, the declaration and payment of future quarterly dividends, if any, will be at the sole discretion of the Board of Directors based on its consideration of various factors, including the company's operating results, financial condition and anticipated capital requirements. Additional information regarding the Series A Mandatory Convertible Preferred Stock can be found within the Company's Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 5, 2025, which can be accessed via the Company's website About Shift4 Shift4 (NYSE: FOUR) is boldly redefining commerce by simplifying complex payments ecosystems across the world. As the leader in commerce-enabling technology, Shift4 powers billions of transactions annually for hundreds of thousands of businesses in virtually every industry. For more information, visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Shift4 intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding Shift4's expectations associated with the declared dividends and future dividend payments. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the substantial and increasingly intense competition worldwide in the financial services, payments and payment technology industries; our ability to continue to expand our share of the existing payment processing markets or expand into new markets; additional risks associated with our expansion into international operations, including compliance with and changes in foreign governmental policies, as well as exposure to foreign exchange rates; and our respective ability to integrate and interoperate each of our services and products with a variety of operating systems, software, devices, and web browsers, and the other important factors discussed under the caption 'Risk Factors' in Part I, Item 1A in Shift4's Annual Report on Form 10-K for the year ended December 31, 2024, as updated by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 and our other filings with the SEC. Any such forward-looking statements represent management's expectations as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, Shift4 disclaims any obligation to do so, even if subsequent events cause our views to change.
